ArticleTherapeutic advances in neurological disorders2019
Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis.
Article in Therapeutic advances in neurological disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07071246 (Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis), which is not on this map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Pooled it
- Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.Therapeutic advances in neurological disorders · 2026Article
- Comparison of outcomes and postoperative immunotherapy between patients with non-thymomatous and thymomatous myasthenia gravis following thymectomy.Therapeutic advances in neurological disorders · 2025Article
- Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.Acta neurologica Belgica · 2024Article
- Rituximab treatment in myasthenia gravis.Frontiers in neurology · 2023Review
- Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.Frontiers in immunology · 2023Review
- New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.Journal of clinical medicine · 2022Review
- Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.Journal of neurology · 2022Article
- A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience.Current journal of neurology · 2022Article
- Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.Handbook of experimental pharmacology · 2022Article
- Benefit and danger from immunotherapy in myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.Frontiers in neurology · 2021Article
- Advances and challenges in the treatment of myasthenia gravis.Therapeutic advances in neurological disorders · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to evaluate the efficacy and safety of repeated low-dose rituximab treatment guided by monitoring circulating CD19+ B cells in patients with refractory myasthenia gravis (MG).
methodsPatients with refractory MG who had received rituximab treatment at two teaching hospitals between September 2013 and January 2017 were reviewed retrospectively. The treatment protocol consisted of an induction treatment with low-dose rituximab (375 mg/m
resultsOf 17 patients, 11 (65%) achieved the primary endpoint, defined as the minimal manifestation or better status with prednisolone ⩽5 mg/day, after median 7.6 months (range, 2-17 months) following rituximab treatment. Over a median follow up of 24 months (range, 7-49 months), a total of 30 retreatments were undertaken due to clinical relapse without B-cell repopulation (
conclusionsThe repeated low-dose rituximab treatment based on the assessment of circulating B-cell depletion could be a cost-effective therapeutic option for refractory MG. Further studies are needed to verify the potentially better cost-effectiveness of low-dose rituximab, and to identify biomarkers that help optimize treatment in MG patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.